← Back to Screener
Arcutis Biotherapeutics, Inc. Common Stock (ARQT)
Price$24.53
Favorite Metrics
Price vs S&P 500 (26W)13.60%
Price vs S&P 500 (4W)0.95%
Market Capitalization$3.04B
All Metrics
Book Value / Share (Quarterly)$1.54
P/TBV (Annual)20.37x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)367.11%
Cash Flow / Share (Quarterly)$-0.13
Price vs S&P 500 (YTD)-19.67%
Gross Margin (TTM)90.24%
Net Profit Margin (TTM)-4.29%
EPS (TTM)$-0.13
10-Day Avg Trading Volume1.03M
EPS Excl Extra (TTM)$-0.13
EPS (Annual)$-0.13
ROI (Annual)-5.41%
Gross Margin (Annual)90.24%
Net Profit Margin (5Y Avg)-19390.75%
Cash / Share (Quarterly)$1.79
Revenue Growth QoQ (YoY)81.48%
ROA (Last FY)-3.73%
Revenue Growth TTM (YoY)91.34%
EBITD / Share (TTM)$-0.09
ROE (5Y Avg)-122.20%
Operating Margin (TTM)-3.25%
Cash Flow / Share (Annual)$-0.13
P/B Ratio16.06x
P/B Ratio (Quarterly)18.77x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)8.27x
Net Interest Coverage (TTM)-3.70x
ROA (TTM)-4.30%
EPS Incl Extra (Annual)$-0.13
Current Ratio (Annual)3.17x
Quick Ratio (Quarterly)2.83x
3-Month Avg Trading Volume1.50M
52-Week Price Return89.27%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.42
P/S Ratio (Annual)8.09x
Asset Turnover (Annual)0.87x
52-Week High$31.77
Operating Margin (5Y Avg)-19198.81%
EPS Excl Extra (Annual)$-0.13
CapEx CAGR (5Y)101.71%
Tangible BV CAGR (5Y)147.92%
26-Week Price Return22.34%
Quick Ratio (Annual)2.83x
13-Week Price Return-8.23%
Total Debt / Equity (Annual)0.57x
Current Ratio (Quarterly)3.17x
Enterprise Value$3,108.591
Asset Turnover (TTM)1.00x
Book Value / Share Growth (5Y)-24.47%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.98x
Pretax Margin (Annual)-3.98%
Cash / Share (Annual)$1.79
3-Month Return Std Dev51.30%
Net Income / Employee (TTM)$-0
ROE (Last FY)-8.52%
Net Interest Coverage (Annual)-1.96x
EPS Basic Excl Extra (Annual)$-0.13
Receivables Turnover (TTM)3.43x
Total Debt / Equity (Quarterly)0.57x
EPS Incl Extra (TTM)$-0.13
Receivables Turnover (Annual)3.43x
ROI (TTM)-6.08%
P/S Ratio (TTM)8.09x
Pretax Margin (5Y Avg)-19390.75%
Revenue / Share (Annual)$2.96
Tangible BV / Share (Annual)$1.42
Forward P/E71.40x
Price vs S&P 500 (52W)54.18%
Year-to-Date Return-15.53%
5-Day Price Return1.70%
EPS Normalized (Annual)$-0.13
ROA (5Y Avg)-48.11%
Net Profit Margin (Annual)-4.29%
Month-to-Date Return4.12%
Cash Flow / Share (TTM)$-4.34
EBITD / Share (Annual)$-0.09
Operating Margin (Annual)-3.25%
LT Debt / Equity (Annual)0.57x
ROI (5Y Avg)-56.15%
LT Debt / Equity (Quarterly)0.57x
EPS Basic Excl Extra (TTM)$-0.13
P/TBV (Quarterly)20.37x
P/B Ratio (Annual)18.77x
Inventory Turnover (TTM)1.98x
Pretax Margin (TTM)-3.98%
Book Value / Share (Annual)$1.54
Price vs S&P 500 (13W)-11.10%
Beta1.64x
Revenue / Share (TTM)$2.93
ROE (TTM)-10.26%
52-Week Low$12.42
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ARQTArcutis Biotherapeutics, Inc. Common Stock | 8.09x | 91.34% | 90.24% | — | $24.53 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company developing topical and systemic treatments for immune-mediated dermatological diseases with significant unmet medical needs. Its lead candidate, ZORYVE (roflumilast cream), has completed Phase 3 trials in plaque psoriasis, demonstrating efficacy and favorable tolerability. The company operates in the dermatology space with a differentiated product portfolio focused on this therapeutic area.